康方生物新药依沃西III期临床试验显著获益

财中社
23 Apr

4月23日,康方生物(09926)发布公告,宣布其全球首创双特异性抗体新药依达方®(依沃西,PD-1/VEGF)在与替雷利珠单抗联合化疗对比的III期临床试验AK112-306/HARMONI-6中,达到了无进展生存期(PFS)的显著阳性结果,具有统计学显著意义和重大临床获益。本研究共入组532例受试者,中央型鳞癌患者占比约为63%。试验结果显示,依沃西联合化疗组在意向治疗人群中相较于对照组,获得...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10